Moderna 8-K
Leadership change
Former Biogen CFO Michael McDonnell joins the Board and Audit Committee; David Rubenstein moves to Nominating and Corporate Governance.
Filed 2026-07-08 07:08 ET
- 5.02 Officer/director change
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Moderna appointed former Biogen CFO Michael McDonnell to its Board, effective 7/8/2026. He will serve as a Class II director through the 2029 annual meeting and join the Audit Committee; David Rubenstein leaves that committee and joins the Nominating and Corporate Governance Committee. McDonnell has more than 35 years of financial leadership experience, including CFO roles at Biogen and other public companies.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3